



Subject: Shingles (Zoster) Vaccine*

Effective Date: April 24, 2007

Department(s): Utilization Management

Policy: Live attenuated Varicella-Zoster Virus vaccine and recombinant, subunit, adjuvanted Varicella-Zoster Vaccine for prevention of herpes zoster are reimbursable under Plans administered by QualCare, Inc. consistent with the recommendations of the Advisory Committee on Immunization Practices of the U.S. Centers for Disease Control and Prevention.

Objective: To provide proper and consistent reimbursement and to delineate criteria for coverage of a specific vaccine.

Procedure: A single dose of live attenuated Varicella-Zoster Virus vaccine (**CPT 90736**) is covered for adults 60 years of age and older, whether or not the individual has had a prior episode of herpes zoster. Two doses of recombinant, subunit, adjuvanted Varicella-Zoster vaccine (CPT 90750)(administered 2 to 6 months apart) is covered for adults 50 years of age and older, regardless of prior history of herpes zoster or administration of live attenuated Varicella-Zoster Virus vaccine.

References

CDC Shingrix Recommendations for Healthcare Professionals- at www.cdc.gov/vaccines/vpd/shingles/hcp/shingrix/recommendations.html

CDC Recommended Immunization Schedule for Adults Aged 19 Years or Older, United States, 2018, at www.cdc.gov/vaccines/schedules/hcp/imz/adult.html

Hales CM, Harpaz R, Ortega-Sanchez I, Bialek SR. Update on recommendations for use of herpes zoster vaccine. *MMWR Morb Mortal Wkly Rep*. 2014;63(33):729-31(Aug)

Boulanger A, Busse JW, Cairns BE, Cooper L et al. Safety and effectiveness of the herpes zoster vaccine to prevent postherpetic neuralgia: 2014 Update and consensus statement from the Canadian Pain Society. *Pain Res Manag*. 2015;20(1):46-7 (Jan-Feb)

Zhang J1, Xie F, Delzell E, Chen L, Winthrop KL et al. Association between vaccination for herpes zoster and risk of herpes zoster infection among older patients with selected immune-mediated diseases. *JAMA*. 2012;308(1):43-9. (Jul)

Tseng HF, Smith N, Harpaz R, Bialek SR, Sy LS, Jacobsen SJ. Herpes zoster vaccine in older adults and the risk of subsequent herpes zoster disease. *JAMA*. 2011;305(2):160-6.(Jan)

Wilson JF. Herpes zoster. *Ann Intern Med*. 2011;154(5):ITC31-15(Mar)

Chen N, Li Q, Zhang Y, Zhou M, Zhou D, He L. Vaccination for preventing postherpetic neuralgia. *Cochrane Database Syst Rev*. 2011 Mar 16;(3):CD007795.

Centers for Disease Control and Prevention. Recommended adult immunization schedule--- United States, 2009. *MMWR* 2008;57(53) Q-1 – Q-4 (Jan 9, 2009)

Heymann WR. The herpes zoster vaccine. *J Am Acad Dermatol* 2008;58(5):872-873 (May)

Betts RF. Vaccination strategies for the prevention of herpes zoster and postherpetic neuralgia. *J Am Acad Dermatol* 2007;57(6 Suppl):S143-S147 (Dec)

Schmader K. Herpes zoster and postherpetic neuralgia in older adults. *Clin Geriatr Med* 2007;23(3):615-632 (Aug)

Centers for Disease Control and Prevention. Recommendations for the Use of Zoster Vaccine. *CDC Morbid Mortal Weekly Rep* (scheduled for publication June 2007)

Kimberlin DW, Whitley RJ. Varicella-Zoster Vaccine for the Prevention of Herpes Zoster. *New Eng J Med* 2007;356(13):1338-1343 (Mar 29)

Zhang AY, Elmets CA, Camp WL, et al. New opportunities in preventative dermatology: How far should we go? *J Am Acad Dermatol* 2007;56(4):675-676 (Apr)

Quirk M. Routine shingles vaccine for US adults over 60. *Lancet Infect Dis* 2006;6(12):761 (Dec)

Centers for Disease Control and Prevention. Advisory Committee on Immunization Practices. ACIP Meeting Minutes pp 1 – 15 October 25 – 26, 2006 available at <http://www.cdc.gov/nip/ACIP/minutes/acip-min-oct06.pdf> (accessed 03/25/07)

----- FDA Licenses New Vaccine to Reduce Older Americans' Risk of Shingles. *FDA News*
May 26, 2006

Oxman MN, Levin MJ, Johnson GR, *et al.* A Vaccine to Prevent Herpes Zoster and Postherpetic Neuralgia in Older Adults. *New Eng J Med* 2005;352(22):2271-2284 (Jun 2)

Drafted By/Date: BFisher, MD 03/25/07
Approved By/Date: QM Committee 04/24/07
Reviewed without Revision By/Date: BFisher, MD 07/23/09
Approved By/Date: QM Committee 09/08/09
Reviewed with Revision By/Date: MMcNeil MD 10/07/11
Approved By/Date: QM Committee 10/25/11
Reviewed w/o Revision By/Date: MMcNeil MD 05/01/15
Approved By/Date: QM Committee, 05/19/15
Reviewed w/o Revision By/Date: MMcNeil, MD 03/23/17
Approved By/Date: QM Committee 4/25/17
Revised By/Date: MMcNeil, MD 10/10/18
Approved By/Date: QM Committee 10/16/18

*Consistent with Summary Plan Description (SPD). When there is discordance between this policy and the SPD, the provisions of the SPD prevail.